Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04970 |
| Species: | Homo sapiens |
| Position : | chr17:6565038-6567038 |
| Year: | 2015 |
| Title: | SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | Fatty Liver Disease |
| PMID: | 25628225 |
| Tissue: | liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | Human Liver Cell |
| Experiment Type: | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| Low Throughput Method: | Luciferase reporter assay; Reporter assay; ChIP-qPCR/ChIP; EMSA/gel-shift assay |
| Target gene : | SLC13A5 |
| TF name : | NR1I2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| NR1I2 | Nuclear Receptor transcription pathway | reactome | 51 |
| NR1I2 | Hs_Drug_Induction_of_Bile_Acid_Pathway_WP2289_88593 | wikipathways | 9 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_04984 | chr17:6285838-6586838 | liver | NA | Steatosis |